chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fever for abut 36 hours ranging from 99-100.6 Body aches Chills Headache Fatigue
Woke up at 1:30am with swollen & numb lips and left ring finger & pinkie finger tingling.
I In office - Tightness of Chest. Pressure in Left Chest.  Same Day Evening - Headache, Nausea, and shortness of breath.  Next Day Morning - Headache, Nausea, randomized Tightness in chest breathing normal, normal heart rythum  Next Day Evening - Headache, Nausea, randomized Tightness in chest ,Welts on legs itchy.  Friday Morning - Burning sensation throughout the legs, HIVES all over the legs, felt like Fire. Tightness in Chest  Friday - forward - Random sets of Chest Pressure, concern of Heart palpatations, and lung capacity.
stomach felt tight; has not had any appetite; This is a spontaneous report received from a non-contactable reporter (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administration date 16Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ABDOMINAL DISCOMFORT (non-serious) with onset 17Mar2021, outcome "unknown", described as "stomach felt tight"; DECREASED APPETITE (non-serious) with onset 17Mar2021, outcome "unknown", described as "has not had any appetite". Additional information: Patient stated that he had his first dose of the Pfizer covid 19 vaccine on 16Mar2021. On the first day, his stomach felt tight and has not had any appetite since.   No follow-up attempts are possible. Information about Lot/batch number cannot be obtained. No further information is expected.
Dizziness, nausea and lightheadedness "hearing voices" due to dizziness. Symptoms reoccurred however 2 wks later.
Unable to move arm above shoulder height, arm pain for 3 day, weakness, possible nerve pain.
woke up 2MAY96 & noted arm soreness & area (red) size of fifty cents piece that was tender to touch & warm;pain from shoulder to elbow;3MAY96 red area sl larger-pain lessened;6MAY96 recovered;
Fever of 102.7 at peak. Treated with ibuprofen a s acetaminophen regimen.  Felt fatigued and ?heavy.?
Caller is an office manager who reports administration of vaccine following temperature excursion. No adverse effects of administration. No further information provided. No other AE/no PQC. Names of vaccines involved (including lot/exp):; Caller is an office manager who reports administration of vaccine following temperature excursion; This spontaneous report was received from an office manager and refers to a patient of unknown age and gender.  The patient's concurrent conditions, medical history and concomitant therapies were not reported.  On an unspecified date, a temperature excursion issue occurred and on 22-APR-2022, the patient was vaccinated with a dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, 2 ml/once, orally, lot #1821247, expiration date: 23-JUL-2022 (strength not provided) as prophylaxis. call was made by an office manager who reported the administration of vaccine following temperature excursion. The vaccine underwent a temperature excursion of 11.4 degree Celsius (C) for a period of 4 hours and 45 minutes. The vaccine underwent a previous temperature excursion at 10.7 C for 1 hour and 15 minutes. The patient did not experience any adverse effects after administration. No further information provided.
The day after vaccine administered rash, redness on lower back with pains, fever 99.5, fatigue. No swelling. (Treatment with steroids).
Vaccine was administered on 10/15/12. Patient awaken the next morning between 6:45-7am on 10/16/12 experiencing coldness within the injection arm and the site was warm to touch. Plus patient complained arm felt weighted down.
Vaccine given after 30-day fridge life. Moderna verified vaccine still okay to administer. No negative outcome.
increased menstrual bleeding; Abnormal menstrual period; This is a spontaneous report received from non-contactable reporter(s) (Pharmacist).  A female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in 2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "COVID" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for Covid-19 Immunisation. The following information was reported: HEAVY MENSTRUAL BLEEDING (non-serious), outcome "unknown", described as "increased menstrual bleeding"; MENSTRUAL DISORDER (non-serious), outcome "unknown", described as "Abnormal menstrual period".  Additional information: The patient reported abnormal menstrual period (increased bleeding) for a couple of months following the bivalent booster last year.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt recvd 3 doses of Recombivax on 20SEP89, 25OCT89, & 5APR90 & 1 booster dose of Engerix-B on 2OCT90 & did not respond;
her son caught covid; interval between the 1st and 2nd dose (8/19/22) and (10/29/22).; This spontaneous case was reported by a patient family member or friend and describes the occurrence of COVID-19 (her son caught covid) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (interval between the 1st and 2nd dose (8/19/22) and (10/29/22).) in a 2-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. AS1412B and AR9236B) for COVID-19 prophylaxis.     No Medical History information was reported.   On 19-Aug-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Oct-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Sep-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (interval between the 1st and 2nd dose (8/19/22) and (10/29/22).). On an unknown date, the patient experienced COVID-19 (her son caught covid). At the time of the report, COVID-19 (her son caught covid) had resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (interval between the 1st and 2nd dose (8/19/22) and (10/29/22).) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was reported.  The reporter stated that the patient received a two-dose Moderna vaccine against COVID-19. The reporter would like to know if those shots was the monovalent covid-19 vaccine type or not. The reporter also stated that the reason for the interval between the 1st and 2nd dose was because the patient caught covid and they had to wait.  No treatment medication information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 08-May-2023: Live non significant follow up received. On 08-May-2023: Live non significant follow up received.
pain/tenderness underneath the arm, "like a band, swollen and tender"; pain/tenderness underneath the arm, "like a band, swollen and tender"; pain/tenderness underneath the arm, "like a band, swollen and tender"; This is a spontaneous report from a contactable nurse.  A 41-year-old female patient received the bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on 19Dec2020 at a single dose for COVID-19 immunization.  The patient's medical history and concomitant medications were not reported. On 27Dec2020, the patient experienced pain/tenderness underneath the arm, "like a band, swollen and tender" (non-serious).  The clinical outcome of the events was unknown.  The batch/lot numbers for the vaccine, PFIZER-BIONTECH COVID-19 MRNA VACCINE, were not provided and will be requested during follow up.
Patient called 1 day after receiving her PNEUMOVAX 23 injection stating she was having immense arm and shoulder pain in the arm the vaccine had been placed (right arm). She stated she could not move her arm to do simple tasks like empty the garbage can or put her coat on. She also stated that she had not slept the previous night. She tried to treat the pain with hydrocodone/APAP that she had left over at her home, but states that she received no relief from that. I advised her that injection site reactions can happen after any vaccine and the best course of action was to apply ice and possibly take an anti-inflammatory (such as ibuprofen). I did advise her to contact her primary care provider if any signs of infection appeared such as redness around the injection site, itching, warm sensation, or weeping from the injection site. I did not hear from the patient until 11/16/18 when she came into our pharmacy again. She stated she had seen her primary care provider. This encounter is described below. The patient states that as of 11/16/18, the pain is getting better, but is still present.
On 11/6/00, states had nasal/sinus symptoms in the morning. On 11/9/00, noticed a rash on chest.
This is a spontaneous report from a contactable healthcare professional received via a Pfizer sales representative. The healthcare professional reported similar events for 3 patients. This is the first of three reports. A female patient of an unspecified age and ethnicity received TRUMENBA, via an unspecified route of administration on an unspecified date, single dose for immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient reported significant reactions in the area of vaccine. Large, pink, hard, wheal like lesions that lasted about 10 days. The patient did not complain about the pain or itching in the area more about the size of the rash. The outcome of the events was recovered on an unspecified date. Sender's Comments: Linked Report(s): US-PFIZER INC-2017340746 same reporter, drug and event/ different patient; US-PFIZER INC-2017340747 same reporter, drug and event/ different patient.
received an extra dose DTap in error with no reported adverse event; twins were prescribed IPV but instead were given the combo vaccine QUADRACEL with no reported adverse event; Initial information received on 26-Jan-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 4 years old male patient who received an extra dose dtap in error with no reported adverse event and twins were prescribed IPV but instead were given the combo diphtheria-15/tetanus/5 hybrid AC pertussis/IPV (MRC5) vaccine [Quadracel] with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included measles vaccine live (enders-edmonston), mumps vaccine live (jeryl lynn), rubella vaccine live (WISTAR RA 27/3), varicella zoster vaccine live (OKA/MERCK) (PROQUAD) for Immunisation.  On 24-Jan-2023, the patient received 0.5 dose of suspect diphtheria-15/tetanus/5 hybrid AC pertussis/IPV (MRC5) vaccine, Suspension for injection, at 1X (once), (lot number: U7526AA: expiry date: 07-Sep-2024) via intramuscular route in the left thigh for immunisation.  On 24-Jan-2023 the patient received an extra dose dtap in error with no reported adverse event (extra dose administered) and twins were prescribed ipv but instead were given the combo vaccine quadracel with no reported adverse event (wrong product administered) (latency: same day) following the administration of diphtheria-15/tetanus/5 hybrid AC pertussis/IPV (MRC5) vaccine.  No lab data was reported.  Action taken was not applicable.  At time of reporting, the outcome was Unknown for all events.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Pharmacist is reporting an MMRII given intramuscularly instead of subcutaneous.; This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reaction or allergy and concomitant therapy was provided.  On 10-OCT-2020, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (0.5 milliliter (ml), batch/lot# and expiration date were unknown, strength was not reported) intramuscularly instead of subcutaneously for prophylaxis (subcutaneous injection formulation administered by other route).
**Pt has complaining of difficulty breathing/swallowing, nausea, body feeling heavy.  Staff observed patient going in and out of consciousness, drooling, and hands cold to the touch.   ** Epi-pen administered at 7:50pm on 4/27/21 and 911 called ** Paramedics arrived and took pt away
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose08/26/21 2nd dose Diagnosed covid positive:09/19/21 Symptom onset: Exposure: Symptoms:fever, cough,fatigue,muscle aches,ABD pain,nausea, diarrhea,chills,runny nose,HA
1527: Patient reports feeling ?hot? and ?heart beating fast"; Dr. responds. Patient received vaccine at 1504. Patient reports ?allergy? to ?perfume smell? and ?smoke?. Reports when he smells perfume and smoke he feels nauseous. Denies anaphylactic reaction. 1529: Dr. and RN assess patient; Initial vitals taken by RN: BP: 150/90, HR: 85, SpO2: 97%RA; Speech is clear and complete, breathing is even and unlabored, skin appears flushed,  Patient is not diaphoretic. Patient declines EMS transport at this time. Patient monitored by Dr.1545:RN present. Vitals assessed by RN BP: 125/82, SpO296%RA, HR:74; 1550: Benadryl 25mg IM (left glute) administered by RN from Verbal Order by Dr. read back and confirmed by RN.  Patient reports his status remains unchanged. RN, RN and Dr. inform patient that because his status remains unchanged a higher level of care is recommended. EMS called by RN. Vitals assessed by Dr.: BP: 170/100, HR: 74, 96%RA; 1606: Fire Engine responds to EMS (911) call, arrives on scene; 1615: Glucose 160mg/dl; 1617: BP 150/90, HR 76, R:18. EMS assessing patient; 1618: Declined EMS transport; 1623: Patient informed by medical staff it is unsafe for him to drive home after Benadryl 25mg IM injection due to drowsiness, patient agreed, transport will be arranged by Manager. 1632: Patient escorted by RN to bathroom. Ambulatory without assistance, Gait is steady. Patient in NAD during walk to bathroom. Patient denies shortness of Breath or chest pain while walking to and from the bathroom. 1646: In person interpreter present. Patient reports he is feeling dizzy and feeling sleepy but he is better, ok? Denies nausea, denies Chest pain, Denies shortness of breath, Denies blurred vision. Skin color normal for patient. Patient is not diaphoretic at present. Speech is clear and complete. Breathing is even and unlabored, patient is  ambulatory without assistance, steady gait. Patient continues to be monitored. 1744: Patient is resting in chair, in no acute distress. Patient has no complaints at this time. 1751: Patient transported home by Employee.
Vaccine was given 10/11/04. Complained of pox on 10/21 or 10/22, injection site red and swollen also. Developed more pox over the next week (>50-100). Complained of feeling tired and denied fever. Recovered by 11/05/04.
Arm swelled up to size of eggplant.  Hot to touch at inj. Location, very painful.  Pain radiated through armpit half-way through breast as well the inflamed deltoid.
His blood pressure was up just a bit; This is a spontaneous report from a contactable consumer (patient). This 80-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number EN6023) via an unspecified route of administration in the top part of the left arm on 27Feb2021 (at the age of 80-years-old) as a single dose for COVID-19 immunisation. Medical history included COPD from an unknown date and unknown if ongoing, reported as diagnosed 3 to 4 years ago and the patient was not taking any medication for it; and blood pressure from an unknown date and unknown if ongoing. The patient reported no family medical history and no adverse events following prior vaccinations. Concomitant medications included atenolol from an unknown date for blood pressure. The patient reported he received his second dose of BNT162B2 on 20Mar2021 for COVID-19 immunisation. The patient reported he did not have any trouble with the first vaccine and that one other thing had happened, and he was unsure if it had anything to do with it or not. He reported he went back to his doctor and had been taking atenolol for blood pressure at a dose of 50/25; his blood pressure went up just a bit and he could not verify who the girl was that changed it to 100/25; also reporting he didn't like the way he felt and eliminated it and went back to the previous dose taking two over a period of 2 to 3 days. The atenolol was in a pharmacy vial and he didn't have the lot or expiration date. The date his blood pressure was up was for the past couple times; further stating it usually was 120/60-70 and then it jumped up to 150/60-70 and that was why it needed to be changed. The patient reported it was filled on 18Mar2021 which was after the first vaccine but before the second dose. The clinical outcome of his blood pressure was up just a bit was unknown.   No follow-up attempts are needed. No further information is expected.
Participant started to get symptom's within 24 hours' of booster vaccine and had to see doctor 72 hour's after vaccine. Had chills, fever, cough, achy bones, generally felt miserable. Symptoms subsided the Sunday after the vaccine.
Large local reaction on rt. arm after injection - warm, swollen, given top. mupirocin, BENADRYL and ZANTAC.
Barely can move arm and having pain in arm; Barely can move arm and having pain in arm; Severe cold like symptoms; Vomiting; This is a spontaneous report received from a contactable reporter (consumer or other non-HCP). The reporter is the patient's son.  A 53-year-old male patient received the second dose of bnt162b2 (BNT162B2) via an unspecified route of administration, administered on the right arm on 21May2021 (batch/lot number: unknown) at the age of 53 years old, as DOSE 2, SINGLE for COVID-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (first dose (manufacturer unknown) via an unspecified route of administration on an unspecified date (batch/lot number: unknown) as DOSE 1, SINGLE) for COVID-19 immunization. The following information was reported: PAIN IN EXTREMITY (non-serious), JOINT RANGE OF MOTION DECREASED (non-serious), outcome "unknown" and all described as "Barely can move arm and having pain in arm"; NASOPHARYNGITIS (non-serious), outcome "unknown" described as "Severe cold like symptoms"; VOMITING (non-serious), outcome "unknown" described as "Vomiting." The clinical course was reported as follows: The reporter stated that his father got the second vaccine yesterday (21May2021). He can barely move his arm and having severe cold like symptoms. He is vomiting. He wanted to know how much are these normal? He has (severe) pain in his arm."  No follow-up attempts are possible; information about the batch/lot number cannot be obtained. No further information is expected.
Redness, warmth, mild tenderness, rash F/U with PCP Advil for pain & inflammation. Cold packs TID x next 24° then warm soaks. If redness worsens pt needs to be seen right away.
appendicitis, appendectomy done on 5/30/21 -- still in recovery phase
joint pain on the legs; Missed dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed dose) and ARTHRALGIA (joint pain on the legs) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     Concomitant products included ACETAMINOPHEN for Joint pain, GABAPENTIN, METOPROLOL, HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL + HIDROCLOROTIAZIDA), NABUMETONE and VITAMIN E NOS for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed dose). On an unknown date, the patient experienced ARTHRALGIA (joint pain on the legs). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed dose) had resolved and ARTHRALGIA (joint pain on the legs) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
This case was reported by a lawyer and described the occurrence of joint pain in a male subject of unspecified age who was vaccinated with LYMErix for prophylaxis. A physician or other health care professional has not verified this report. On an unspecified date the subject received unspecified dose of LYMErix (unknown). At an unspecified time after vaccination with LYMErix, the subject experienced joint pain, joint swelling, fatigue, visual problem, headache, nerve injury, possible autoimmune disease and activities of daily living impaired. At the time of reporting the outcome of the events was unspecified. This information was received via a Statement of Injuries. Follow up information was received on 19 July 2007 via medical records. Medical history included an automobile accident, tick bites including "multiple" deer tick bites during the summer of 1996, joint pain including shoulder pain, and neck pain. The subject was a male in his late-thirties who was vaccinated with LYMErix on 15 May 1999, 11 June 1999, and 12 July 2000. At the time of his third LYMErix vaccination on 12 July 2000, he was noted to be in "good health with no major problems except for hyperlipidemia. " On 26 July 2000, the subject was evaluated for a "strabismus-type deficit". A computed tomography (CT) scan showed preliminary normal results. Upon examination, he appeared to have a right lateral rectus palsy. It was noted that he had fallen a few weeks prior to examination and had struck the back of his head. The evaluation physician suspected a contrecoup injury with a sixth nerve pulse, and the subject was referred for a neurological evaluation. The case was assessed upon follow up to be medically significant by GSK. In October 1999, the subject was diagnosed with gastroenteritis. A progress note dated 13 July 2000 indicated that the subject "hurt his back at work", and received Naprosyn, Flexeril, and Percocet. These were considered to be incidental findings upon medical record review.
Persistent right arm pain after vaccine.  Vaccine 21 Oct with pain out of proportion in posterior right deltoid at time of flu immunization injection that persisted.  Patient seen by PCM 10 November and then seen by provider 21 November.  Received steroid injection in right shoulder which made pain worse x 1 week and pending PT referral.
Minutes after receiving immunization, chills, then red, itchy eyes, fever, threw up 2x, dry, swollen tonsils. Still feeling weak 4 days later.